HIMS & HARE HEALTH (NYSE: HIMS) Positions itself to take advantage Novo Nordisk’s (NYSE: NVO) Assembly -Wire for weight loss market, while the Danish pharmaceutical giant is struggling with falling turnover and a CEO change.
Novo Nordisk ended his collaboration with him and her in May and accused the telehealth company of “illegal massage” and “misleading marketing” of his weight loss treatments. The pharmaceutical giant claimed that HIMS and Hare did not adhere to laws that banned the mass sales of worsened medicines under the ‘false disguise of personalization’.
In particular, Hims & Hare does not seem to be surprised by the accusations. In the profit call of the second quarter (Q2), HIMS maintained the confidence in his weight loss specialty, in the expectation to deliver at least US $ 725 million in income this year in its extensive range, including oral treatments and personalized composite GLP-1’s.
As an alternative, Novo Nordisk recently cut his guidelines for the entire year, with reference to weaker growth meter expectations for Wegovy on the American market. The Healthcare Heavyweight now expects revenue growth from only 8% to 14%, for an earlier goal from 13% to 21%.
“For Wegovy in the US, the sales prospects reflects the ongoing use of composite GLP-1’s, slower than expected market expansion and competition,” Novo Nordisk essentially explained that companies like Hims & Hare eat in its market share.
Is HIMS a good buy at the moment?
During the income call of Q2, Hims & Hass CEO Andrew Dudum emphasized that the platform gives priority to “protection of the importance of consumers” and ensures that providers maintain “full independence in decision -making”. It reported to serve more than 2.4 million subscribers, with strong retention rates in its weight loss programs.
While Novo Nordisk is struggling with disappointing test results for his next generation of obesity medicine and fights negative sentiment that has driven his stock this year by more than 42%, Hims & Hare is expanding internationally and launches new specialties such as Hormonal Health.
The problems of the Danish giant can offer the TeleHealth Disruptor the opportunity to settle as a viable alternative in the lucrative market for weight management.
HIMS & HARE displayed a strong financial momentum with a revenue growth of 73% on an annual basis up to US $ 545 million in Q2, while retaining healthy adapted income before interest, tax, depreciation and amortization margins above 15%.
The company’s subscriber base grew to 2.4 million, with strong retention rates, because only 25% of weight loss customers stopped to six months compared to 80% in some public studies.
HIMS launches hormonal health treatments for more than 50 million Americans who have to deal with low testosterone and menopause symptoms. An important strategic move includes the acquisition of a blood test laboratory to offer extensive home tests, creating a stand-alone income flow and at the same time supporting preventive care initiatives.
What is the purpose of the Him’s stock price?
Analysts who follow the sale of HIMS forecast to increase US $ 1.48 billion to US $ 3.8 billion in 2024 in 2024 in 2029. Compared to that the adjusted income in this period will expand from US $ 0.95 per share to US $ 3.03 per share.
Nowadays, the HIMS shares is priced at 36 times ahead in the win, which is reasonable considering the growths. If it can retain a similar appreciation, the HIMS shares could more than double over the next three years.
Analysts remain bullish and predict the shares of HIMs to win 15% in the coming 12 months, given the objectives of the consensus.
#Hims #Hare #Health #cash #Novo #Nordisk #Blunderer